Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss.

Liu H, Golji J, Brodeur LK, Chung FS, Chen JT, deBeaumont RS, Bullock CP, Jones MD, Kerr G, Li L, Rakiec DP, Schlabach MR, Sovath S, Growney JD, Pagliarini RA, Ruddy DA, MacIsaac KD, Korn JM, McDonald ER 3rd.

Nat Med. 2019 Jan;25(1):95-102. doi: 10.1038/s41591-018-0302-5. Epub 2018 Dec 17.

PMID:
30559422
2.

Corrigendum: Genetic interrogation of replicative senescence uncovers a dual role for USP28 in coordinating the p53 and GATA4 branches of the senescence program.

Mazzucco AE, Smogorzewska A, Kang C, Luo J, Schlabach MR, Xu Q, Patel R, Elledge SJ.

Genes Dev. 2017 Nov 15;31(22):2310. doi: 10.1101/gad.309864.117. No abstract available.

3.

Genetic interrogation of replicative senescence uncovers a dual role for USP28 in coordinating the p53 and GATA4 branches of the senescence program.

Mazzucco AE, Smogorzewska A, Kang C, Luo J, Schlabach MR, Xu Q, Patel R, Elledge SJ.

Genes Dev. 2017 Oct 1;31(19):1933-1938. doi: 10.1101/gad.304857.117. Erratum in: Genes Dev. 2017 Nov 15;31(22):2310.

4.

Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC.

Elife. 2017 Oct 31;6. pii: e33173. doi: 10.7554/eLife.33173. No abstract available.

5.

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.

McDonald ER 3rd, de Weck A, Schlabach MR, Billy E, Mavrakis KJ, Hoffman GR, Belur D, Castelletti D, Frias E, Gampa K, Golji J, Kao I, Li L, Megel P, Perkins TA, Ramadan N, Ruddy DA, Silver SJ, Sovath S, Stump M, Weber O, Widmer R, Yu J, Yu K, Yue Y, Abramowski D, Ackley E, Barrett R, Berger J, Bernard JL, Billig R, Brachmann SM, Buxton F, Caothien R, Caushi JX, Chung FS, Cortés-Cros M, deBeaumont RS, Delaunay C, Desplat A, Duong W, Dwoske DA, Eldridge RS, Farsidjani A, Feng F, Feng J, Flemming D, Forrester W, Galli GG, Gao Z, Gauter F, Gibaja V, Haas K, Hattenberger M, Hood T, Hurov KE, Jagani Z, Jenal M, Johnson JA, Jones MD, Kapoor A, Korn J, Liu J, Liu Q, Liu S, Liu Y, Loo AT, Macchi KJ, Martin T, McAllister G, Meyer A, Mollé S, Pagliarini RA, Phadke T, Repko B, Schouwey T, Shanahan F, Shen Q, Stamm C, Stephan C, Stucke VM, Tiedt R, Varadarajan M, Venkatesan K, Vitari AC, Wallroth M, Weiler J, Zhang J, Mickanin C, Myer VE, Porter JA, Lai A, Bitter H, Lees E, Keen N, Kauffmann A, Stegmeier F, Hofmann F, Schmelzle T, Sellers WR.

Cell. 2017 Jul 27;170(3):577-592.e10. doi: 10.1016/j.cell.2017.07.005.

6.

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC.

Elife. 2017 Feb 1;6. pii: e18970. doi: 10.7554/eLife.18970. Erratum in: Elife. 2017 Oct 31;6:.

7.

CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions.

Munoz DM, Cassiani PJ, Li L, Billy E, Korn JM, Jones MD, Golji J, Ruddy DA, Yu K, McAllister G, DeWeck A, Abramowski D, Wan J, Shirley MD, Neshat SY, Rakiec D, de Beaumont R, Weber O, Kauffmann A, McDonald ER 3rd, Keen N, Hofmann F, Sellers WR, Schmelzle T, Stegmeier F, Schlabach MR.

Cancer Discov. 2016 Aug;6(8):900-13. doi: 10.1158/2159-8290.CD-16-0178. Epub 2016 Jun 3.

8.

Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.

Mavrakis KJ, McDonald ER 3rd, Schlabach MR, Billy E, Hoffman GR, deWeck A, Ruddy DA, Venkatesan K, Yu J, McAllister G, Stump M, deBeaumont R, Ho S, Yue Y, Liu Y, Yan-Neale Y, Yang G, Lin F, Yin H, Gao H, Kipp DR, Zhao S, McNamara JT, Sprague ER, Zheng B, Lin Y, Cho YS, Gu J, Crawford K, Ciccone D, Vitari AC, Lai A, Capka V, Hurov K, Porter JA, Tallarico J, Mickanin C, Lees E, Pagliarini R, Keen N, Schmelzle T, Hofmann F, Stegmeier F, Sellers WR.

Science. 2016 Mar 11;351(6278):1208-13. doi: 10.1126/science.aad5944. Epub 2016 Feb 11.

9.

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.

Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P, Balak M, Raza A, Ackley E, Keen N, Schlabach MR, Palmer M, Leary RJ, Chiang DY, Sellers WR, Michor F, Cooke VG, Korn JM, Stegmeier F.

Nat Med. 2015 May;21(5):440-8. doi: 10.1038/nm.3841. Epub 2015 Apr 13.

PMID:
25849130
10.

A chemical genetics approach for the functional assessment of novel cancer genes.

Zhou Q, Derti A, Ruddy D, Rakiec D, Kao I, Lira M, Gibaja V, Chan H, Yang Y, Min J, Schlabach MR, Stegmeier F.

Cancer Res. 2015 May 15;75(10):1949-58. doi: 10.1158/0008-5472.CAN-14-2930. Epub 2015 Mar 18.

11.

Recurrent hemizygous deletions in cancers may optimize proliferative potential.

Solimini NL, Xu Q, Mermel CH, Liang AC, Schlabach MR, Luo J, Burrows AE, Anselmo AN, Bredemeyer AL, Li MZ, Beroukhim R, Meyerson M, Elledge SJ.

Science. 2012 Jul 6;337(6090):104-9. doi: 10.1126/science.1219580. Epub 2012 May 24.

12.

A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.

Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R, Shaw CA, Elledge SJ, Westbrook TF.

Science. 2012 Jan 20;335(6066):348-53. doi: 10.1126/science.1212728. Epub 2011 Dec 8.

13.

Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.

Scholer-Dahirel A, Schlabach MR, Loo A, Bagdasarian L, Meyer R, Guo R, Woolfenden S, Yu KK, Markovits J, Killary K, Sonkin D, Yao YM, Warmuth M, Sellers WR, Schlegel R, Stegmeier F, Mosher RE, McLaughlin ME.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17135-40. doi: 10.1073/pnas.1104182108. Epub 2011 Sep 23.

14.

Synthetic design of strong promoters.

Schlabach MR, Hu JK, Li M, Elledge SJ.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2538-43. doi: 10.1073/pnas.0914803107. Epub 2010 Jan 21.

15.

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.

Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ.

Cell. 2009 May 29;137(5):835-48. doi: 10.1016/j.cell.2009.05.006.

16.

Design of 240,000 orthogonal 25mer DNA barcode probes.

Xu Q, Schlabach MR, Hannon GJ, Elledge SJ.

Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2289-94. doi: 10.1073/pnas.0812506106. Epub 2009 Jan 26.

17.

Cancer proliferation gene discovery through functional genomics.

Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, Westbrook TF, Liang AC, Chang K, Hackett JA, Harper JW, Hannon GJ, Elledge SJ.

Science. 2008 Feb 1;319(5863):620-4. doi: 10.1126/science.1149200. Erratum in: Science.2008 Apr 18;320(5874):316.

18.

Profiling essential genes in human mammary cells by multiplex RNAi screening.

Silva JM, Marran K, Parker JS, Silva J, Golding M, Schlabach MR, Elledge SJ, Hannon GJ, Chang K.

Science. 2008 Feb 1;319(5863):617-20. doi: 10.1126/science.1149185.

19.

Second-generation shRNA libraries covering the mouse and human genomes.

Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ, Siolas D, Hu G, Paddison PJ, Schlabach MR, Sheth N, Bradshaw J, Burchard J, Kulkarni A, Cavet G, Sachidanandam R, McCombie WR, Cleary MA, Elledge SJ, Hannon GJ.

Nat Genet. 2005 Nov;37(11):1281-8. Epub 2005 Oct 2.

PMID:
16200065
20.

A genetic screen for candidate tumor suppressors identifies REST.

Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, Zhao JJ, Roberts TM, Mandel G, Hannon GJ, Depinho RA, Chin L, Elledge SJ.

Cell. 2005 Jun 17;121(6):837-48.

21.
22.

The nonspecific binding of Fe3+ to transferrin in the absence of synergistic anions.

Bates GW, Schlabach MR.

J Biol Chem. 1975 Mar 25;250(6):2177-81.

23.

A study of the anion binding site of transferrin.

Bates GW, Schlabach MR.

FEBS Lett. 1973 Jul 15;33(3):289-92. No abstract available.

24.

The reaction of ferric salts with transferrin.

Bates GW, Schlabach MR.

J Biol Chem. 1973 May 10;248(9):3228-32. No abstract available.

25.

Does transferrin exhibit ferroxidase activity?

Bates GW, Workman EF Jr, Schlabach MR.

Biochem Biophys Res Commun. 1973 Jan 4;50(1):84-90. No abstract available.

PMID:
4683626

Supplemental Content

Loading ...
Support Center